As one of the most common @entity5 , the clinical and socio-economic consequences of @entity2 are significant. Currently, surgery is the main treatment strategy for this disease, but the survival rates of @entity2 @entity1 are not ideal due to the high recurrence rate of the disease. Therefore, many researchers are exploring new specific therapeutic methods that are highly curative and minimally cytotoxic to healthy tissues. To this end, albumin nanospheres simultaneously were loaded with super-paramagnetic @entity1933 nanoparticles (as gene vector and anticancer gene), and plasmid pDONR223- @entity379 , and modified with anti- @entity470 monoclonal antibody cetuximab as therapy. Targeting agents, namely gene-loaded immunomagnetic albumin nanospheres (cetuximab [C225]- @entity379 -IMANS), were prepared for targeted @entity2 cells ( @entity1 cell lines). Transmission electron microscopy images showed that the C225- @entity379 -IMANS were successfully prepared, and the ability of the nanospheres to target @entity1 cells in vitro was confirmed by Prussian blue staining, immunofluorescence experiments, and magnetic resonance imaging. Transfection photographs and agarose gel electrophoresis proved that pDONR223- @entity379 could be encased in the albumin nanospheres. A Cell Counting Kit-8 assay showed that the combination therapy group had significantly more therapeutic effects on @entity1 cells than other therapy groups. A flow cytometry assay showed that the apoptotic index of the combined treatment group was 67.68%, whereas the indices of the C225 group, gene therapy group, and magnetic fluid @entity221 group were 12.2%, 16.34%, and 20.04% respectively. Therefore, the combination of thermal treatment, molecular targeted treatment, and gene treatment synergistically targets @entity1 cells, and the use of C225- @entity379 -IMANS as a gene or drug carrier offers a novel and promising approach for the treatment of @entity2 .

The study on the preparation and characterization of gene-loaded immunomagnetic albumin nanospheres and their anti-cell proliferative effect combined with magnetic fluid @entity221 on XXXX cells.

@entity1 :: ('9606', 'Species') :: ['patients', 'GLC-82'] @entity5 :: ('MESH:D009369', 'Disease') :: ['malignant tumors'] @entity470 :: ('1956', 'Gene') :: ['EGFR'] @entity2 :: ('MESH:D008175', 'Disease') :: ['lung cancer', 'lung carcinoma'] @entity1933 :: ('MESH:C000499', 'Chemical') :: ['iron oxide'] @entity379 :: ('3458', 'Gene') :: ['IFNG'] @entity221 :: ('MESH:D005334', 'Disease') :: ['hyperthermia']
@entity1 :: (9606,Species) :: ['GLC-82']
